In recent research led by the University of California San Diego School of Medicine, scientists have found a new potential treatment for obstructive...
Vous n'êtes pas connecté
Researchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study demonstrating the potential of tirzepatide, known to manage type 2 diabetes, as the first effective drug therapy for obstructive sleep apnea (OSA), a sleep-related disorder characterized by repeated episodes of irregular breathing due to complete or partial blockage of the upper airway.
In recent research led by the University of California San Diego School of Medicine, scientists have found a new potential treatment for obstructive...
FRIDAY, June 21, 2024 -- A medication used to manage type 2 diabetes has been found effective in treating sleep apnea.The worldwide clinical trial...
WEDNESDAY, June 26, 2024 -- Tirzepatide reduces the apnea-hypopnea index (AHI) among individuals with moderate-to-severe obstructive sleep apnea and...
New research showed that tirzepatide, the compound in Zepbound, improved symptoms of obstructive sleep apnea.
Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales...
Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing...
Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder
Blood tests offer a promising method to predict a person's risk of developing obstructive sleep apnea by measuring levels of specific biomarkers.
FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with...
Measuring blood levels of homocysteine, an medlinkamino acid/medlink, can predict a person's risk of developing medlinkobstructive sleep...